InMed Pharmaceuticals (INM) Competitors $2.69 +0.14 (+5.49%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. EQ, CTXR, PHIO, ME, AYTU, LIPO, ATHA, NEUP, NERV, and AIMDShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Equillium (EQ), Citius Pharmaceuticals (CTXR), Phio Pharmaceuticals (PHIO), 23andMe (ME), Aytu BioPharma (AYTU), Lipella Pharmaceuticals (LIPO), Athira Pharma (ATHA), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Minerva Neurosciences (NERV), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Equillium Citius Pharmaceuticals Phio Pharmaceuticals 23andMe Aytu BioPharma Lipella Pharmaceuticals Athira Pharma Neuphoria Therapeutics Inc. - Common Stock Minerva Neurosciences Ainos Equillium (NASDAQ:EQ) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Do institutionals & insiders believe in EQ or INM? 27.0% of Equillium shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 31.6% of Equillium shares are held by company insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, EQ or INM? InMed Pharmaceuticals has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$30.41M0.45-$13.34M-$0.39-0.99InMed Pharmaceuticals$4.92M0.66-$7.68M-$12.09-0.22 Does the media refer more to EQ or INM? In the previous week, InMed Pharmaceuticals had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for InMed Pharmaceuticals and 1 mentions for Equillium. Equillium's average media sentiment score of 1.87 beat InMed Pharmaceuticals' score of 0.96 indicating that Equillium is being referred to more favorably in the media. Company Overall Sentiment Equillium Very Positive InMed Pharmaceuticals Positive Does the MarketBeat Community prefer EQ or INM? Equillium received 28 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 80.00% of users gave Equillium an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3680.00% Underperform Votes920.00% InMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% Which has more risk and volatility, EQ or INM? Equillium has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Do analysts prefer EQ or INM? Equillium presently has a consensus price target of $3.00, suggesting a potential upside of 676.20%. Given Equillium's stronger consensus rating and higher possible upside, equities research analysts plainly believe Equillium is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EQ or INM more profitable? Equillium has a net margin of -10.05% compared to InMed Pharmaceuticals' net margin of -163.75%. Equillium's return on equity of -20.68% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% InMed Pharmaceuticals -163.75%-90.74%-71.70% SummaryEquillium beats InMed Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.25M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.208.6727.1419.96Price / Sales0.66262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.536.597.064.69Net Income-$7.68M$143.75M$3.23B$248.14M7 Day Performance-14.87%3.72%2.67%2.39%1 Month Performance17.98%11.01%8.82%6.05%1 Year Performance-43.79%3.87%31.44%13.60% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals0.8189 of 5 stars$2.69+5.5%N/A-46.7%$3.25M$4.92M-0.2010Short Interest ↓EQEquillium3.1628 of 5 stars$0.38flat$3.00+689.5%-46.9%$13.57M$30.41M-2.7140Positive NewsGap UpCTXRCitius Pharmaceuticals2.4298 of 5 stars$1.37+61.0%$54.50+3,878.1%-93.7%$13.46MN/A0.0020News CoverageAnalyst ForecastGap UpHigh Trading VolumePHIOPhio Pharmaceuticals3.7813 of 5 stars$2.79-5.7%$14.00+401.8%-62.2%$13.39MN/A-0.2610Short Interest ↓Analyst RevisionGap UpME23andMeN/A$0.50-35.3%N/A-94.0%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeAYTUAytu BioPharma1.4893 of 5 stars$2.11+5.5%N/A-36.4%$13.02M$81.66M-1.46160Short Interest ↓Gap UpHigh Trading VolumeLIPOLipella Pharmaceuticals2.1051 of 5 stars$2.91-2.7%N/A-46.4%$13.00M$536.36K-0.684ATHAAthira Pharma2.8772 of 5 stars$0.33-8.1%$13.83+4,079.3%-87.4%$12.92MN/A-0.1240NEUPNeuphoria Therapeutics Inc. - Common Stock2.0286 of 5 stars$6.82-0.7%$21.00+207.9%N/A$12.92M$15.66M0.00N/ANERVMinerva Neurosciences3.4281 of 5 stars$1.84flat$5.00+171.7%-44.6%$12.87MN/A-4.189News CoverageAIMDAinos1.3923 of 5 stars$0.62-6.2%N/A-35.3%$12.84M$106.21K-0.4840Gap Down Related Companies and Tools Related Companies EQ Alternatives CTXR Alternatives PHIO Alternatives ME Alternatives AYTU Alternatives LIPO Alternatives ATHA Alternatives NEUP Alternatives NERV Alternatives AIMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INM Stock Free INM Stock Alerts